fill in the blanks

What is the name of the company referred to the following article?

"_ _ _ _ _ _ _ _ , an Australian-founded _ _ _ _ _ _ _ _ _ _ _ _, is keen to list on a larger US exchange, either the NASDAQ or NYSE, in 2015, said CEO _ _ _ _ _ _. The listing is aimed at raising the company’s profile with a larger group of investors, especially institutional ones, as it transitions from a clinical microcap to a global commercial company, _ _ _ _ _ said."

I will provide a clue. Paul Watt is a former director.

The answer of course is Avita Medical. The excerpt is from a February 2015 article posted in their newsroom on the Avita website.

Could the Phylogica Board consider a similar direction? If you wondered why the presentation at the Biotech Showcase event in San Francisco was worthy of a public announcement perhaps we have an answer. Biotech Showcase is an investor and partnering conference providing exposure to US biotech specialist investors as well as pharmaceutical company executives.

The impression that I have formed from a number of sources is that Phylogica is excited about the data in relation to its in-house oncology programs, excited about the level of access in Big Pharma and excited about the progress made at the recent JP Morgan biotech conference. The big question faced is how to 'transition from a clinical microcap to a global commercial company' in a jaded local market.

To take destiny into one's own hands will require investors who see the promise of the bigger picture. Bump along the bottom or take the ride to the top!